Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investor Events
  • Pre-market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
March 14, 2024 3:59 PM 2 min read

German Conglomerate Bayer Goes Johnson & Johnson Way To Tackle Its Cancer Related Lawsuits

by Vandana Singh Benzinga Editor
Follow

Bayer AG (OTC:BAYRY) (OTC:BAYZF) is reportedly considering utilizing the Texas Two-Step bankruptcy approach to tackle the onslaught of lawsuits in the United States implicating its Roundup weedkiller causing cancer. 

With an array of recent expensive jury verdicts weighing heavily on the company, executives are strategizing with legal experts to employ this controversial tactic to halt upcoming trials and negotiate a comprehensive settlement for over 50,000 cases. 

Also Read: Bayer Holds Splitting Into Separate Units For Three Years, Focus Shifts On Tackling Challenges.

This maneuver, named after a Texas state law, entails segregating assets and liabilities into distinct units, subsequently filing the liability-loaded unit for bankruptcy to facilitate a global resolution. 

Bloomberg noted that similar attempts by companies like 3M Co (NYSE:MMM) and Johnson & Johnson (NYSE:JNJ) were rebuffed by courts in separate litigations.

Facing significant financial repercussions, Bayer is seeking respite following a barrage of adverse verdicts totaling around $4 billion in the past four months alone. 

While the company has secured victories in recent trials, including some substantial reductions in awarded damages, a Pennsylvania jury’s recent $2.25 billion ruling against Bayer underscores the gravity of the situation. 

A Pennsylvania jury has ordered Bayer’s Monsanto to pay over $2.2 billion to former Roundup user John McKivison, who attributed his cancer to the popular weedkiller. 

The verdict, the largest in the five-year Roundup litigation, includes $250 million for compensatory losses and $2 billion in punitive damages. McKivison, a 49-year-old landscaper, claimed prolonged exposure to Roundup led to his non-Hodgkins lymphoma diagnosis in 2020.

Citing Bruce Markell, a former federal bankruptcy judge and current law professor at Northwestern University, the Wall Street Journal report acknowledges the long odds Bayer faces with the Texas Two-Step but underscores the company’s limited alternatives. 

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Photo via Wikimedia Commons

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.


Posted In:
BiotechLarge CapNewsHealth CareLegalGeneralAI GeneratedBriefsStories That Matter
BAYRY Logo
BAYRYBayer AG
Not Available-%
Overview
BAYZF Logo
BAYZFBayer AG
$30.72-43.8%
JNJ Logo
JNJJohnson & Johnson
$244.720.52%
MMM Logo
MMM3M Co
$171.82-%
BAYRY Logo
BAYRYBayer AG
Not Available-%
Overview
BAYZF Logo
BAYZFBayer AG
$30.72-43.8%
JNJ Logo
JNJJohnson & Johnson
$244.720.52%
MMM Logo
MMM3M Co
$171.82-%
Comments
Loading...